JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Затворен

4.17 -1.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.1

Максимум

4.19

Ключови измерители
By Trading Economics
Приходи	4M -3.8M
Продажби	522K 1.1M
EPS	-0.014
Марж на печалбата	-357.374
Служители	19
EBITDA	75K -7.6M

Дивиденти
By Dow Jones
Следващи печалби	13.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	67M 906M
Предишно отваряне	5.59
Предишно затваряне	4.17

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Пазарно говорене

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24.04.2026 г., 17:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.04.2026 г., 17:11 ч. UTC

Пазарно говорене

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Пазарно говорене

Печалби

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 17:06 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24.04.2026 г., 16:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

24.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.